What Are the Benefits and Risks of Semaglutide Injectable with B12?
Semaglutide injectable with B12 is a compounded weekly shot that puts semaglutide and a B12 form in the same vial. It is not FDA-approved. Approved pens do not contain B12. STEP-1 evidence for 2.4 mg approved semaglutide does not automatically apply to this mix.
Written for Dominia Health education · Reviewed by Ariel Bowerman, BSN, R.N. · Last evidence check: September 2026
Semaglutide injectable with B12 is a compounded weekly shot that puts semaglutide and a B12 form (cyanocobalamin, methylcobalamin, or hydroxocobalamin) in the same vial. It is not FDA-approved. Approved pens do not contain B12. STEP-1 evidence for 2.4 mg approved semaglutide does not automatically apply to this mix. FDA has said combining semaglutide with B12 "has not been established" as safe or effective.
This page covers compounded injectable semaglutide + B12 at standard strengths and the lower-dose "microdose" version, which has its own section below: Microdose option: what's different.
Last evidence check: September 2026. No dedicated randomized trial of same-vial semaglutide plus B12 has been published, at standard or microdose strengths.
What Is in the Vial
A compounded vial is intended to contain semaglutide plus a B12 salt. Wegovy injection starts at 0.25 mg weekly and maintains at 2.4 mg. Compounded strengths vary. Some compounded products have used salt forms (semaglutide sodium or acetate) that are not the base used in approved drugs. Multi-dose vials raise sterility questions after the first puncture. Use only the instructions from the prescriber and pharmacy. Do not convert internet "units."
Why Clinics Add B12 Instead of Giving It Separately
Clinics often say B12 may help energy or offset low B12. B12 deficiency is a real, separate issue. Same-vial mixing is not the same as a B12 tablet or a separate B12 shot. Ingredient evidence ≠ combination evidence. There is no established trial that same-vial B12 improves weight loss.
What Is Proven vs. Unproven
| Item | FDA-approved injectable semaglutide | Compounded injectable + B12 |
|---|---|---|
| Status | FDA-approved (Wegovy, Ozempic) | Not FDA-approved |
| Typical weekly dose | Start 0.25 mg; Wegovy 2.4 mg maintenance | Varies by pharmacy; "microdose" vials usually below 0.25 mg |
| Weight-loss evidence | STEP-1: −14.9% at 68 weeks on 2.4 mg | No dedicated RCTs of this mix |
| B12 in same syringe | No | Yes; combo not FDA-reviewed |
| Distinctive signal | Labeled risks | FDA: combo not established; vial dosing errors; 990 compounded-semaglutide AE reports as of May 31, 2026 |
STEP-1 (Wilding et al., NEJM, Feb. 10, 2021): −14.9% vs −2.4% placebo at week 68 on 2.4 mg weekly injection. About 86% on semaglutide lost at least 5% of body weight versus 32% on placebo. Those figures describe FDA-approved semaglutide at the maintenance dose, not a compounded B12 combination.
Risks That Apply to Any Injectable Semaglutide
| Effect (STEP 1–3, 2.4 mg vs placebo) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Nausea | 43.9% | 16.1% |
| Diarrhea | 29.7% | 15.9% |
| Vomiting | 24.5% | 6.3% |
| Constipation | 24.2% | 11.1% |
| Stopped for GI events (STEP-1) | 4.5% | 0.8% |
Most GI events were mild to moderate and clustered during dose increases.
Serious labeled risks include pancreatitis, gallbladder disease, dehydration/kidney injury, hypoglycemia with certain diabetes drugs, possible retinopathy worsening, and a boxed warning about thyroid C-cell tumors in rodents. Avoid with MTC or MEN2.
Risks Unique to Compounded Vials and Same-Vial B12
FDA's compounded-semaglutide dosing-error alert describes patients drawing 5 to 20 times the intended dose from multi-dose vials after mixing up units, milligrams, and milliliters. Some were hospitalized. Reported events included severe GI symptoms, fainting, dehydration, pancreatitis, and gallstones. FDA states in the same document that adding cyanocobalamin (B12) and other extras (it also names B6, L-carnitine, and NAD) has not been established as safe or effective.
As of May 31, 2026, FDA reported 990 adverse-event reports associated with compounded semaglutide as a class. That count is for compounded semaglutide products as a group, not a proven rate for every B12 vial.
Lilly's March 12, 2026 letter described a chemical adduct when tirzepatide was mixed with B12. That finding is about tirzepatide, not semaglutide. It does not prove the same impurity exists here. It does show why "B12 in the syringe is just a vitamin" is not an evidence-based claim.
Research-use-only vials sold for people are not recommended.
Who Might Discuss This with a Prescriber
A clinician may discuss FDA-approved semaglutide if you meet labeled criteria. Same-vial B12 is a different product. Avoid MTC/MEN2, relevant allergy, and research-only listings. A clinician may also flag other problems, including a history of pancreatitis, and pregnancy decisions belong with the clinician.
How This Differs from Wegovy or Ozempic
Approved pens have no B12 in the device. Compounded is not a generic. Brand names appear here only because FDA and the trials used them.
Microdose Option: What's Different
"Microdose" is a clinic word, not an FDA-defined strength. FDA-approved Wegovy injection starts at 0.25 mg once weekly for four weeks, then steps to 0.5 mg, 1 mg, 1.7 mg, and a 2.4 mg maintenance dose. Ozempic starts at 0.25 mg weekly for diabetes, with different maintenance doses. Compounded semaglutide + B12 sold as a "microdose" is usually prepared below 0.25 mg weekly, and that range was not the efficacy dose in STEP-1.
- Evidence: No trial has tested microdose semaglutide with B12. The STEP-1 numbers above come from the 2.4 mg maintenance dose, far above the sub-0.25 mg range microdose vials use, so they say even less about this version.
- Risks: The microdose vial carries the same labeled semaglutide risks, the same FDA dosing-error warning for multi-dose vials, and the same unestablished B12 combination described above. A lower labeled strength does not make the vial FDA-reviewed.
- Who it is discussed for: adults already being evaluated for medical weight management who understand that the mix is compounded, that microdose is not the STEP-1 2.4 mg dose, and that FDA has not established the B12 combination. The prescriber evaluates. This page does not.
From Our Founders
"I read FDA's footnote that B12 in the same semaglutide product has not been established as safe or effective. STEP-1's 15% figure is for 2.4 mg approved pens, not a compounded B12 vial at any strength. Talk to your provider about which product you would actually inject." — Ariel Bowerman, BSN, R.N.
Frequently Asked Questions
What are the benefits and risks of semaglutide injectable with B12? Benefits are inferred from approved 2.4 mg semaglutide, not proven for this mix. Risks include usual GI effects, FDA-documented vial dosing errors, and an unstudied combination.
Does compounded semaglutide with B12 have FDA approval? No. Compounded drugs are not FDA-approved, whether the vial is standard strength or "microdose."
Will the added B12 boost weight loss? That has not been established. Do not treat B12 as a weight-loss booster.
What does "microdose" mean for this shot? Clinics usually mean a weekly amount below the 0.25 mg labeled Wegovy start. It is not an FDA-defined dose. See Microdose option: what's different.
Can B12 be given on its own instead of in the same injection? A clinician can treat B12 deficiency with a separate product. Same-vial mixing is what FDA says has not been established.
What did FDA say about B12 and other add-ins in compounded semaglutide? FDA reported dosing errors from multi-dose vials and stated that combining semaglutide with B12 and other add-ins has not been shown safe or effective.
How common is nausea, and what else is typical? In STEP 1–3, nausea occurred in about 44% on 2.4 mg approved semaglutide versus 16% on placebo, followed by diarrhea, vomiting, and constipation. Those are not rates for this compounded mix.
Who should avoid a semaglutide–B12 vial? People with MTC/MEN2, a relevant allergy, or anyone offered a research-only vial. A clinician decides the rest.
Is this the same as Wegovy or Ozempic? No. Compounded semaglutide is not a generic of either.
Bottom Line
FDA-approved 2.4 mg semaglutide has established trial data. Compounded injectable with B12 is not FDA-approved at standard or microdose strength. FDA has not established the combination, and vial dosing errors have sent some patients to the hospital. Do not treat B12 as a weight-loss booster.
So what? Ask whether you would receive an approved pen or a compounded B12 vial — and whether B12 can be given separately.
Have questions about medical weight management? Talk with a licensed healthcare provider. To learn more or request a consultation, visit Dominia Health.
Sources:
- Wilding JPH, et al. STEP-1. NEJM 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- FDA dosing errors alert — compounded semaglutide (includes B12 footnote). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- FDA unapproved GLP-1 concerns (990 compounded-semaglutide AE reports as of May 31, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA compounding Q&A. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Lilly open letter, March 12, 2026. https://investor.lilly.com/news-releases/news-release-details/open-letter-eli-lilly-and-company-warning-potential-patient
- Wegovy prescribing information, starting dose 0.25 mg (FDA label). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031lbl218316s003lbl.pdf
Written by: Dominia Health education
Medically reviewed by: Ariel Bowerman, BSN, R.N.
Published: September 10, 2026 · Updated: October 10, 2026
Explore Topics
Written by
Ariel Bowerman, BSN, R.N.
Content creator and writer sharing insights and stories.
